Ipsen, Pharnext deal

Pharnext granted Ipsen an exclusive option to an exclusive license to develop and commercialize an undisclosed compound plus two follow-on compounds to treat Charcot-Marie-Tooth disease in the U.S., Europe, China and certain other territories. The compounds are based on Pharnext's Pleotherapy technology, which combines low doses of existing, off-patent drugs for new indications based on human genetics and pharmacology. Pharnext has a compound that uses the technology in preclinical testing for the indication with plans to start Phase I testing next year. ...